A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 主要目的：检测在标准放化疗的基础上加用西妥昔单抗是否能降低至少50%的局部失败率。 次要目标： 1)通过描述CMT和西妥昔单抗在CMT期间和第一年内病毒载量、CD4计数、机会性疾病发生率(包括艾滋病的发展)的变化来表征CMT加西妥昔单抗对潜在HIV状况的影响。 2)探讨CMT治疗对肛门生殖道HPV感染及肛周细胞学的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim: To detect whether the addition of cetuximab to standard chemoradiation reduces the local failure rate by at least 50% Secondary Aims: 1) To characterize the effect of CMT plus cetuximab on the underlying HIV condition by describing changes in viral load, CD4 counts, incidence of opportunistic illnesses including the development of AIDS during and in the first year after CMT. 2) To evaluate the effect of CMT of anal cancer on anogenital HPV infection and anal cytology.